Physician

Salil Shukla, MD

According to 2025 Medicare claims, Salil Shukla, MD (NPI: 1154595171) practices ophthalmology in the Denver-Aurora-Centennial, CO market, with the plurality of this provider's patient population coming from Arapahoe, CO. This provider's primary affiliated billing organization is COLORADO RETINA ASSOCIATES, PLLC (NPI: 1790876159; TIN: 203288374) and primary practice location at 80134-5640.

Shukla's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 781 traditional Medicare patients, billed 36,196 HCPCS/CPT codes, and received $3,646,176 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 162 prescription claims across 113 beneficiaries totaling $15,398 in drug costs, led by Neomycin-Polymyxin-Dexameth (Neomycin/Polymyxin B/Dexametha). Open Payments data shows 33 records totaling $1,164. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $948,492 to $3,646,176. In contrast, Part D prescription costs have fallen sharply in recent years, from $13,215 to $15,398. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.8M$3.6M2015 Medicare payment: $948,492 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,420,162 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,686,070 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $1,636,343 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $1,405,757 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,545,037 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,978,573 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,237,658 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,729,848 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $3,646,176 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20156504,924$948,492
20166595,880$1,420,162
20176806,259$1,686,070
20186927,241$1,636,343
20196466,813$1,405,757
20205946,033$1,545,037
20217028,382$1,978,573
202275310,867$2,237,658
202370829,051$2,729,848
202478136,196$3,646,176

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$7.7K$15K2015 Drug cost: $13,215 (USD; Tot_Drug_Cst)2016 Drug cost: $11,568 (USD; Tot_Drug_Cst)2017 Drug cost: $13,053 (USD; Tot_Drug_Cst)2018 Drug cost: $12,921 (USD; Tot_Drug_Cst)2019 Drug cost: $10,248 (USD; Tot_Drug_Cst)2020 Drug cost: $9,230 (USD; Tot_Drug_Cst)2021 Drug cost: $5,239 (USD; Tot_Drug_Cst)2022 Drug cost: $6,117 (USD; Tot_Drug_Cst)2023 Drug cost: $4,159 (USD; Tot_Drug_Cst)2024 Drug cost: $15,398 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201554108$13,215
20165297$11,568
201760122$13,053
201871133$12,921
201958116$10,248
202077168$9,230
202198140$5,239
202293154$6,117
202396141$4,159
2024113162$15,398

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg1691,258$655
67028Injection of drug into eye3521,579$108
92014Established patient complete exam of visual system542788$97
99426Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month116633$53
92134Imaging of retina7602,303$32

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha962,225$1,198
Prednisolone AcetatePrednisolone Acetate26769$895

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.33$1,164Genentech, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Salil Shukla, MD?

Tedicare shows public-source Medicare data for Salil Shukla, MD (NPI 1154595171), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Salil Shukla, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Salil Shukla, MD?

Salil Shukla, MD is linked to COLORADO RETINA ASSOCIATES, PLLC (billing NPI 1790876159) in the available physician profile data.

Does Salil Shukla, MD have Open Payments data?

Salil Shukla, MD has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.